An investigational aldose reductase inhibitor (ARI), govorestat is being developed for treating several rare diseases. The NDA is supported by data demonstrating a quick and lasting decline in ...

central nervous system (CNS)-penetrant aldose reductase inhibitor (ARI), for the treatment of Classic Galactosemia." According to the Company, "[t]he CRL indicates that the FDA completed its ...

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its ...